Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric CancerTip Ranks·Jul 27 at 11:07 PM02162+0.21%AZN-0.99%
Connovo-B falls 8% in Hong Kong trading on no catalystHK Stock Market Update·Jul 27 at 09:00 PM02162+0.21%
Keymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II TrialsTip Ranks·Jul 22 at 11:07 PM02162+0.21%
Keymed Biosciences advances Phase II trials for CM512 across multiple respiratory and inflammatory indicationsPUBT·Jul 22 at 11:01 PM02162+0.21%
Keymed Biosciences says China regulator grants breakthrough therapy designation for CM512 in CRSwNPPUBT·Jul 22 at 11:00 PM02162+0.21%
KEYMED BIO-B Expects Interim Turnaround to Profit of at Least RMB1.2BAASTOCKS News·Jul 15 at 08:40 PM02162+0.21%AZN-0.99%
Keymed Biosciences Swings to Profit on Kangyueda Surge and Licensing WindfallTip Ranks·Jul 15 at 10:09 AM02162+0.21%AZN-0.99%
Conba-B rises over 8% after CITIC initiates with Buy ratingHK Stock Market Update·Jul 15 at 12:10 AM02162+0.21%
Concordia Bio Hits Record High on Hong Kong TradingHK Stock Market Update·Jul 6 at 09:00 PM02162+0.21%
HSI Up 266 pts; HSTI Up 42 pts; TENCENT Up over 4%; MEITUAN Up over 4%; KEYMED BIO-B Hit New Highs; Market Turnover RisesAASTOCKS News·Jul 6 at 03:15 AM00HSI+0.10%MPNGY-0.29%
HSI Closes Midday at 23,542, Up 192 pts; HSTI Closes Midday at 4,551, Up 52 pts; TENCENT Up over 3%; KEYMED BIO-B Hit New HighsAASTOCKS News·Jul 5 at 11:20 PMSTECH+0.53%00HSI+0.10%
Conventor-B rises 8% in Hong Kong trading to HK$76.2HK Stock Market Update·Jul 1 at 09:40 PM02162+0.21%
Concentric-B Surges 10% As China Biomedicine Policy Boosts SectorHK Stock Market Update·Jun 28 at 09:12 PM02162+0.21%